Michael C. James - Aug 29, 2025 Form 4 Insider Report for GUIDED THERAPEUTICS INC (GTHP)

Role: Director
Signature: /s/ Michael C James
Stock symbol: GTHP
Transactions as of: Aug 29, 2025
Transactions value $: $5,000
Form type: 4
Date filed: 9/5/2025, 11:50 AM
Previous filing: Jun 13, 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
JAMES MICHAEL C	Director	5835 PEACHTREE CORNERS EAST, SUITE B, PEACHTREE CORNERS	/s/ Michael C James	2025-09-05	0001365831

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	GTHP	Common Stock	Purchase	$5K	+27.8K	+5.28%	$0.18	553K	Aug 29, 2025	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	GTHP	Warrants	Purchase		+27.8K	+111.11%		52.8K	Aug 29, 2025	Common Stock	27.8K	$0.25	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On August 29, 2025, the Company entered into a Securities Purchase Agreement with Mr. James, pursuant to which the Company agreed to sell, for a total price of $5,000, an aggregate of 27,778 units, each unit consisting of one share of common stock and one warrant to purchase up to 27,778 shares of common stock (the "August Warrants"). The August Warrants were immediately exercisable upon issuance and will expire in four years following the issuance date and have an exercise price of $0.25 per share.

Content

On August 29, 2025, the Company entered into a Securities Purchase Agreement with Mr. James, pursuant to which the Company agreed to sell, for a total price of $5,000, an aggregate of 27,778 units, each unit consisting of one share of common stock and one warrant to purchase up to 27,778 shares of common stock (the "August Warrants"). The August Warrants were immediately exercisable upon issuance and will expire in four years following the issuance date and have an exercise price of $0.25 per share.